The BH3-mimetic ABT-737 inhibits allogeneic immune responses

Transplant International

Volumn 24, Issue 7, 2011, Pages 722-732

  Cippà, Pietro E ^a,b   Kraus, Anna K ^a,b   Edenhofer, Ilka ^a   Segerer, Stephan ^a,b   Chen, Jin ^a,b   Hausmann, Martin ^b   Liu, Yang ^a,b   Guimezanes, Annick ^c   Bardwell, Philip D ^d   Wüthrich, Rudolf P ^a,b   Fehr, Thomas ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d ABBOTT LABORATORIES   (United States)

Author keywords

ABT 737; Allograft; Apoptosis; Bcl 2; Immunosuppression; Transplantation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BCL 2;

ALLOGENEIC IMMUNE RESPONSE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CELL MEDIATED LYMPHOLYSIS; CELL PROLIFERATION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; INTESTINE EPITHELIUM CELL; LOW DRUG DOSE; LYMPHOID CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SKIN GRAFT; SKIN TRANSPLANTATION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 80955180005     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01272.x     Document Type: Article

References (20)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
2. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922.
3. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109(Suppl.): S97.
4. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303.
5. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361: 1570.
6. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677.
7. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321.
8. Carrington EM, Vikstrom IB, Light A, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA 2010; 107: 10967.
9. Bardwell PD, Gu J, McCarthy D, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol 2009; 182: 7482.
10. Schulze DH, Pease LR, Geier SS, et al. Comparison of the cloned H-2Kbm1 variant gene with the H-2Kb gene shows a cluster of seven nucleotide differences. Proc Natl Acad Sci USA 1983; 80: 2007.
11. Auphan N, Curnow J, Guimezanes A, et al. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice. Eur J Immunol 1994; 24: 1572.
12. Guimezanes A, Barrett-Wilt GA, Gulden-Thompson P, et al. Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence. Eur J Immunol 2001; 31: 421.
13. Segerer S, Hudkins KL, Taneda S, et al. Oral interferon-alpha treatment of mice with cryoglobulinemic glomerulo-nephritis. Am J Kidney Dis 2002; 39: 876.
14. Segerer S, Eitner F, Cui Y, Hudkins KL, Alpers CE. Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques. J Am Soc Nephrol 2002; 13: 370.
15. Grossmann J, Walther K, Artinger M, et al. Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). Eur J Cell Biol 2003; 82: 262.
16. Ludwinski MW, Sun J, Hilliard B, et al. Critical roles of Bim in T cell activation and T cell-mediated autoimmune inflammation in mice. J Clin Invest 2009; 119: 1706.
17. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728.
18. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360.
19. Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. J Immunol 2010; 185: 2555.
20. Wilson WH, Tulpule A, Levine AM, et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood 2007; 110: Abstract 1371.